Cargando…

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids

BACKGROUND: A considerable number of children with asthma remain symptomatic despite treatment with inhaled corticosteroids, resulting in significant morbidity, reduced quality of life, increased healthcare costs and lost school days. The aim of our study was to assess the efficacy, safety and toler...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vogelberg, Christian, Moroni-Zentgraf, Petra, Leonaviciute-Klimantaviciene, Migle, Sigmund, Ralf, Hamelmann, Eckard, Engel, Michael, Szefler, Stanley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331449/ https://www.ncbi.nlm.nih.gov/pubmed/25851298 http://dx.doi.org/10.1186/s12931-015-0175-9

Ejemplares similares

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

O05 - Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study
por: Vogelberg, Christian, et al.
Publicado: (2014)

Forced Expiratory Flow (FEF(25–75%)) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis
por: Szefler, Stanley J., et al.
Publicado: (2020)

Efficacy and Safety of Tiotropium in Children and Adolescents
por: Hamelmann, Eckard, et al.
Publicado: (2018)

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
por: Vogelberg, Christian, et al.
Publicado: (2019)

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
por: Hamelmann, Eckard, et al.
Publicado: (2017)

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
por: Beeh, Kai-Michael, et al.
Publicado: (2014)

Tiotropium respimat(®) add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status
por: Yang, WH, et al.
Publicado: (2014)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
por: Ohta, Ken, et al.
Publicado: (2015)

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis
por: Halpin, David M. G., et al.
Publicado: (2020)

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results
por: Bradley, Judy M., et al.
Publicado: (2014)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

A comparison of tiotropium, long-acting β(2)-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Commentary: Treating Pediatric Asthma According Guidelines
por: Szefler, Stanley, et al.
Publicado: (2019)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

In Vitro Determination of Respimat(®) Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
por: Bickmann, Deborah, et al.
Publicado: (2016)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
por: Dahl, Ronald, et al.
Publicado: (2015)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study
por: Trotta, Francesco, et al.
Publicado: (2015)

Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2016)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids
por: Hodder, Richard, et al.
Publicado: (2007)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
por: Mark FitzGerald, J., et al.
Publicado: (2020)

Bronchodilator Effect of Tiotropium via Respimat(Ⓡ) Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Ogasawara, Takashi, et al.
Publicado: (2017)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6fgs8sd69c9n8o38m5rnh1c52r